# Pizarra — PT-pseudo_180352970ace (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_180352970ace
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.116 ng/mL²
  - PSA velocity: 1.18 ng/mL/yr
  - Prior PSA: 2.8 ng/mL
  - Prostate volume: 31.97 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7869916 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 32 mL. csPCa 0.79.

Vitals: weight 71 kg, height 183 cm, BMI 21.2, BP 124/82 mmHg, HR 84 bpm. Smoking: Non-smoker.

Chief complaint: Clinical concern stems from a sustained increase in prostate-specific antigen levels coupled with a newly identified high-risk lesion on multiparametric magnetic resonance imaging.

History: At sixty-three years of age, this self-employed carpentry contractor presents with a minimal International Prostate Symptom Score of 5/35, despite an initial workup for hesitancy and frequency two years prior. Prior biopsy bucket: None. He has never wed and resides with his partner, while his grown daughter acts as the designated emergency contact. A strict non-smoker, his daily routine features biweekly tennis matches and a weekly alcohol intake hovering around fourteen units. Medical background remains entirely clear, with no comorbidities or active prescriptions. He denies haematuria, skeletal discomfort, or unaccounted weight reduction, and has arranged for an Arabic interpreter to facilitate his next consultation.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The gland exhibits no focal irregularities, aligning with a benign digital assessment. Hemodynamic parameters show a blood pressure of 124/82 mmHg and a pulse of 84 beats per minute. Systemic evaluation notes a well-built individual in comfortable repose, featuring unremarkable pulmonary fields and a steady cardiac rhythm upon auscultation.

Patient info: self-employed contractor (carpentry); Never married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 14 units / week; exercise Tennis 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.75 +/- 0.10   (95% CI 0.56-0.95)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.81 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI prose confirm the PI-RADS 5 finding and provide context for the lesion size/zone comparison?
  - psa_trend (get_psa_trend) -> Does the PSA history show a significant trend or velocity that warrants immediate action?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on integrating the high-risk imaging finding (PI-RADS 5) with the PSA trend and prior management context to confirm the guideline recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (3.7 ng/mL), PI-RADS 5, PSA density (0.116 ng/mL²), and csPCa probability (0.7869916). It cannot weigh the qualitative context provided by the mpMRI prose, the PSA velocity (1.18 ng/mL/yr), or the prior management context (no prior biopsy).

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.75), but the guideline criterion is based on PI-RADS $\ge 3$, which is met. However, the guideline notes that a PI-RADS 5 lesion is the highest risk, and the prior does not account for the potential for overdiagnosis associated with high-risk findings. Furthermore, the prior does not account for the PSA velocity (1.18 ng/mL/yr) or the DRE being normal, which might suggest a less aggressive clinical picture than the high csPCa probability suggests.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI prose confirm the PI-RADS 5 finding and provide context for the lesion size/zone comparison?
psa_trend - Does the PSA history show a significant trend or velocity that warrants immediate action?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the full laboratory results to assess PSA density context?
GUIDELINE ANCHOR
The guideline states that a PI-RADS $\ge 3$ triggers biopsy, and the track record for this criterion is high.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate Multiparametric MRI | Institution: Catharina Ziekenhuis, Eindhoven | Date: 15 January 2025
FINDINGS: A discrete 12 mm focus of hypointensity occupies the right mid peripheral zone on T2-weighted sequences. Diffusion-weighted imaging shows pronounced signal restriction, mirrored by corresponding ADC hypointensity. Extracapsular extension, seminal vesicle involvement, nodal enlargement, and skeletal metastases are absent.
IMPRESSION: PI-RADS 5 lesion in the right mid peripheral zone. Prostate volume 31.97 mL. PSA density 0.116 ng/mL/mL. csPCa predicted probability 0.7869916.

get_psa_trend
[{"date": "Oct 2022", "val": 1.6}, {"date": "Jul 2023", "val": 2.1}, {"date": "Apr 2024", "val": 2.8}, {"date": "Jan 2025", "val": 3.7}]

get_previous_notes
[{"date": "24 Jan 2024", "author": "Dr. K. Bakker (GP)", "text": "During a standard check-in, laboratory results placed the prostate-specific antigen at 2.8 ng/mL, highlighting a consistent climb from earlier values. No bothersome voiding complaints or constitutional symptoms were noted. Urology consultation was arranged to investigate the upward trend."}, {"date": "29 Jan 2023", "author": "Dr. K. Bakker (GP)", "text": "A scheduled assessment noted a prostate-specific antigen reading of 1.8 ng/mL, edging past prior reference points. Occasional daytime urinary frequency was reported, though obstructive features remained absent."}]

NOT RETRIEVED
laboratory panel
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and the retrieved documents did not raise a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid peripheral zone.
- PSA trend: PSA velocity of 1.18 ng/mL/yr, with a recent rise to 3.7 ng/mL.
- Previous notes: Patient was referred to urology to investigate an upward trend in PSA.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the high-risk PI-RADS 5 finding on MRI, which aligns with the guideline criterion. This confirms the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 on MRI, PSA velocity, and prior consultation context) strongly supports the guideline criterion for biopsy. The laboratory panel was not retrieved as it was not explicitly required by the agenda.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 5 lesion, which was confirmed by the retrieved MRI report. This finding was decisive, aligning with the statistical prior and the protocol. The PSA velocity of 1.18 ng/mL/yr and the prior consultation context further reinforced this conclusion, leading to a clear recommendation for sampling.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
